In this clinical trial, the investigators are proposing the addition of Elotuzumab to Selinexor and low-dose dexamethasone (ESd) in RRMM, previously treated with one or a combination of PI's, IMiD's, and anti-CD38 mAb.
This is an upcoming trial that has not yet started accepting patients.
The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.
Patients must meet all of the following inclusion criteria to be eligible to enroll in this study:
Patients meeting any of the following exclusion criteria are not eligible to enroll in this study:
Enrollment: 18 patients (estimated)View More
View all clinical trial locations sorted by state.
New Orleans, LA
If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.
You can explore trial locations from around the US and connect directly with a trial coordinator.Find Nearby Locations
You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.
Still need help? Send us a message